Susan Quello
Scripps Research Institute
9 Papers
21 Citations
Susan Quello is an academic researcher from Scripps Research Institute. The author has contributed to research in topics: Alcohol dependence & Medicine. The author has an hindex of 5, co-authored 6 publications.
Chat about Author
Papers
Gabapentin treatment for alcohol dependence: a randomized clinical trial
TL;DR: Gabapentin was effective in treating alcohol dependence and relapse-related symptoms of insomnia, dysphoria, and craving, with a favorable safety profile and increased implementation of pharmacological treatment of alcohol dependence in primary care may be a major benefit of gabapentin as a treatment option for alcohol dependence.
A Proof-of-Concept Randomized Controlled Study of Gabapentin: Effects on Cannabis Use, Withdrawal and Executive Function Deficits in Cannabis-Dependent Adults
Barbara J. Mason,Rebecca D. Crean,Vivian Goodell,John M. Light,Susan Quello,Farhad F. Shadan,Kimberly Buffkins,Mark Kyle,Murali Adusumalli,Adnan Begovic,Santosh Rao +10 more
TL;DR: This phase IIa proof-of-concept pilot study provides preliminary support for the safety and efficacy of gabapentin for treatment of cannabis dependence, and provides an alternative conceptual framework for Treatment of addiction aimed at restoring homeostasis in brain stress systems that are dysregulated in drug dependence and withdrawal.
219
Gabapentin for the treatment of alcohol use disorder.
TL;DR: Evidence from single-site studies lend support to the safety and efficacy of gabapentin as a novel treatment for alcohol use disorder, with unique benefits for alcohol-related insomnia and negative affect, relative to available treatments.
97
Screening for Co-Occurring Mental Disorders in Drug Treatment Populations:
TL;DR: In this article, a first step is assessment of such comorbid disorders among the clients of substance abuse treatment organizations, and a second step is the assessment of the patients' co-occurring psychiatric disorders.
18
The FDA-approved drug apremilast suppresses alcohol intake: clinical and pre-clinical validation
Kolter B. Grigsby,Regina A. Mangieri,Amanda J. Roberts,Marcelo F. Lopez,Alex Tran,Evan J. Firsick,Kayla G. Townsley,Beneze A,Bess J,Eisenstein Tk,Meissler Jj,John M. Light,Miller J,Susan Quello,Shadan F,Skinner M,Heather C. Aziz,Pamela Metten,Morissett Ra,John C. Crabbe,Marisa Roberto,Howard C. Becker,Barbara J. Mason,Angela R. Ozburn +23 more
TL;DR: In this article, apremilast, a phosphodiesterase type 4 inhibitor that is FDA approved for psoriasis and psoriatic arthritis, reduces binge-like alcohol intake and behavioral measures of motivation in unique, preclinical genetic risk models for drinking to intoxication and reduces excessive alcohol drinking in models of stress-facilitated drinking and alcohol dependence.
6